Engineered T Cells Show Promise Against Deadly Mesothelioma Cancer
Small trial tests modified immune cells injected directly into chest cavity to fight aggressive cancer with 12-month survival rate.
Summary
Researchers at University of Zurich completed a phase I safety trial testing engineered T cells against malignant pleural mesothelioma, an aggressive cancer with poor prognosis. The study enrolled 4 patients who weren't candidates for surgery and modified their immune cells to target cancer-specific proteins. Scientists extracted T cells from patients' blood, genetically reprogrammed them with chimeric antigen receptors to recognize FAP proteins on cancer cells, then injected one million modified cells directly into the chest cavity. This personalized immunotherapy approach represents a novel treatment strategy for patients facing median survival of just 12 months with standard chemotherapy.
Detailed Summary
University of Zurich researchers completed a groundbreaking phase I clinical trial testing engineered T cell therapy for malignant pleural mesothelioma, an aggressive cancer affecting the chest lining with extremely poor outcomes. The study targeted patients ineligible for surgical intervention who typically survive only 12 months with palliative chemotherapy.
The trial enrolled 4 participants and tested a personalized immunotherapy approach. Scientists extracted T cells from each patient's blood 21 days before treatment, then genetically modified these immune cells using retroviral technology to express chimeric antigen receptors targeting FAP proteins found on mesothelioma cells.
Patients received a single dose of one million re-engineered T cells injected directly into their pleural effusion, the fluid accumulation in the chest cavity characteristic of this cancer. This direct delivery method aimed to concentrate the therapeutic cells at the tumor site while minimizing systemic side effects.
The trial ran from February 2015 to July 2018, focusing primarily on safety assessment rather than efficacy outcomes. This CAR-T cell approach represents a significant advancement in personalized cancer treatment, where patients' own immune systems are reprogrammed to recognize and attack their specific tumors.
While detailed results aren't publicly available, the completion of this safety trial paves the way for larger studies. The research demonstrates the feasibility of targeting FAP-positive cancers with engineered immune cells, potentially offering hope for patients with limited treatment options and contributing to the broader field of immunotherapy that may extend healthy lifespan by providing more effective cancer treatments.
Key Findings
- Phase I safety trial successfully completed testing engineered T cells in 4 mesothelioma patients
- Modified immune cells targeted FAP proteins specifically found on cancer cells
- Direct injection into chest cavity concentrated treatment at tumor site
- Personalized approach used each patient's own reprogrammed immune cells
Methodology
Phase I safety trial with 4 participants over 3.5 years. Single-arm design testing fixed dose of 1 million CAR-T cells. No control group as this was primarily a safety and feasibility study.
Study Limitations
Very small sample size limits statistical power and generalizability. Safety-focused design provides limited efficacy data. Single-dose approach may not optimize therapeutic potential of engineered T cells.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.